
Opinion|Videos|August 23, 2024
Clinical Data Supporting Pneumococcal Vaccination
Key opinion leaders examine the pivotal clinical data that supported the FDA approvals of PCV15, PCV20, and PCV21, while also explaining the differences between polysaccharide and conjugate pneumococcal vaccines in terms of their induced immune responses and the durability of protection they offer.
Advertisement
Episodes in this series

What is the key data that led to the FDA-approvals of PCV15, PCV20, and PCV21?
How do the polysaccharide and conjugate pneumococcal vaccines differ in terms of immune response and durability?
- Can you discuss the potential long-term benefits of using conjugate vaccines over polysaccharide vaccines in adult populations and vice versa?
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacy Is a Practice, Not Just a Place
2
Beat the Heat: 10 Common Medication Culprits Causing Heat Intolerance
3
Yes, COVID-19 Is Still a Big Deal. Pharmacy Is the Tip of the Spear (and Needle)
4
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
5


































































































